3:30pm Chair Introduction

Lior Raviv, Chief Technical Officer, Pluri

3:35pm Presentation: Manufacturing T cells in Closed Systems at Scale – Opportunities to Maximise Efficiency and Eradicate Variability

• The technology used for the manufacture of autologous and medium-scale allogeneic T cell products
• Where inefficiencies exist and what technological solutions can bring
• Preparing for success – cryopreservation of larger numbers of doses from a single manufacturing run

John Campbell, Executive in Residence, Delin Ventures

3:50pm Presentation: Technology Strategies for Manufacturing Advanced Therapies

• Leverage Lessons from Development
• Coordinate and Track Manufacturing in Real-Time
• Be Ready to Release

Michalle Adkins, Director Life Sciences, Emerson 

4:05pm Presentation: Implement Automation To Increase Reproducibility and Flexibility for Multiple Concurrent Clinical Trials

• Using several automated systems for an end-to-end automated closed process
• Manufacturing reproducibility across programs
• Building an operationally efficient and robust clinical manufacturing facility

Arnaud Deladeriere, Director of Process Development, Triumvira Immunologics

4:20pm Presentation: CGX10 Cell Isolation System Evaluation

Evaluation of the CGX10 cell isolation system, focusing on the performance, closed system aspect, GMP compliance and handling for cell therapy purposes

Wissam Baghdadi, Engineer Process development, Sangamo Therapeutics

4:35pm Presentation: New Developments and Technologies to Expand your Cell & Gene Therapy Possibilities

• Overview of cell manufacturing platform and update on new developments
• Insights and experience with a fully automated T cell manufacturing processes
• Novel options for automated and closed non-viral engineering, final filling and large-scale cultivation

Melanie Rietenbach, Global Product Manager, Immunotherapy, Miltenyi Biotec

4:50pm Closing Q&A

With all session participants